Drugs / GST-HG171
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06087055 | May → Jun 2023 | — | Fujian Akeylink Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06084507 | May 2023 | COVID-19 | Fujian Akeylink Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06106113 | Dec 2022 → Feb 2023 | pneumonia | Fujian Akeylink Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05668897 | Oct → Dec 2022 | COVID-19 | Fujian Akeylink Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT05656443 | Dec 2022 → May 2023 | pneumonia | Fujian Akeylink Biotechnology Co., Ltd. | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT06106126 | Feb 2023 → Feb 2024 | pneumonia | Fujian Akeylink Biotechnology Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-11-25 | Fujian Cosunter Pharmaceutical Co. Ltd | Regulatory 广生堂一类创新药泰中定(阿泰特韦片联合利托那韦片)获得国家药品监督管理局批准上市 cosunter.com ↗
阿泰特韦片（项目代号：GST-HG171）/利托那韦片组合包装（商品名：泰中定）获国家药品监督管理局（以下简称“国家药监局”）附条件批准上市，并收到《药品注册证书》。 |
| 2023-01-14 | Fujian Cosunter Pharmaceutical Co. Ltd | Results 广生中霖完成2.2亿元融资，全速推进创新药研发上市 cosunter.com ↗
泰中定 ( 试验组 ) 中位转阴时间为 8.4 天， Paxlovid( 阳性对照组 ) 中位转阴时间为 9.5 天，安慰剂组中位转阴时间为 10.3 天。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-25 | Fujian Cosunter Pharmaceutical Co. Ltd | 广生堂一类创新药泰中定(阿泰特韦片联合利托那韦片)获得国家药品监督管理局批准上市 cosunter.com ↗ |
| 2023-01-14 | Fujian Cosunter Pharmaceutical Co. Ltd | 广生中霖完成2.2亿元融资，全速推进创新药研发上市 cosunter.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GST-HG171 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06087055 ↗ |
| Known as | atilotrelvir | “GST-HG171 (also known as atilotrelvir) is a novel, orally administered 3CL protease inhibitor approved in China for treating mild-to-moderate COVID-19.” PMID 42112804 ↗ May 2026 |
| Action | Inhibit | “3C like protease inhibitor” PMID 38618202 ↗ Apr 2024 |
| Modality | Small molecule | “orally bioavailable small-molecule 3C like protease inhibitor” PMID 38618202 ↗ Apr 2024 |
| Route | Oral | “orally administered GST-HG171 plus Ritonavir” PMID 38618202 ↗ Apr 2024 |